Literature DB >> 6260657

Type-common and type-specific monoclonal antibody to herpes simplex virus type 1.

L Pereira, T Klassen, J R Baringer.   

Abstract

Hybridoma cells produced by fusing mouse myeloma cells with spleen cells from mice primed with herpes simplex virus (HSV) type 1 yielded five clones producing neutralizing antibody against homologous virus. Two clones, HCl and HC2, produced antibody capable of precipitating glycoprotein C and its precursor, whereas three clones, HD1, HD2, and HD3, produced antibody capable of precipitating glycoprotein D and its precursor. Antibody produced by the HC1 and HC2 clones neutralized HSV type 1 but not HSV type 2 or HSV type 1 strain MP, which is known to lack glycoprotein C. Antibody produced by the HD1 and HD2 clones neutralized both HSV type 1 and HSV type 2, whereas antibody produced by the HD3 clone neutralized HSV type 1 but not HSV type 2. The two clones which produced antibody to glycoprotein C and the two clones which produced type-common antibody to glycoprotein D were independently derived and not clonally related inasmuch as the antibody in each pair belonged to a different subclass of immunoglobulin.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6260657      PMCID: PMC551186          DOI: 10.1128/iai.29.2.724-732.1980

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  24 in total

1.  The role of type specific and cross reacting structural antigens in the neutralization of herpes simplex virus types 1 and 2.

Authors:  C Sim; D H Watson
Journal:  J Gen Virol       Date:  1973-05       Impact factor: 3.891

2.  Immunological specificity of the glycoproteins of herpes simplex virus subtypes 1 and 2.

Authors:  T Savage; B Roizman; J W Heine
Journal:  J Gen Virol       Date:  1972-10       Impact factor: 3.891

3.  Variability of herpes simplex virus: isolation of two variants from simultaneous eruptions at different sites.

Authors:  M Terni; B Roizman
Journal:  J Infect Dis       Date:  1970-02       Impact factor: 5.226

4.  Proteins spcified by herpes simplex virus. II. Viral glycoprotins associated with cellular membranes.

Authors:  P G Spear; B Kellejmroian
Journal:  J Virol       Date:  1970-02       Impact factor: 5.103

5.  Proteins specified by herpes simplex virus. 3. Viruses differing in their effects on the social behavior of infected cells specify different membrane glycoproteins.

Authors:  J M Keller; P G Spear; B Roizman
Journal:  Proc Natl Acad Sci U S A       Date:  1970-04       Impact factor: 11.205

6.  Type-specific protein in herpes simplex virus envelope reacts with neutralising antibody.

Authors:  K L Powell; A Buchan; C Sim; D H Watson
Journal:  Nature       Date:  1974-05-24       Impact factor: 49.962

7.  Characterization of herpes simplex virus strains differing in their effects on social behaviour of infected cells.

Authors:  P M Ejercito; E D Kieff; B Roizman
Journal:  J Gen Virol       Date:  1968-05       Impact factor: 3.891

8.  A film detection method for tritium-labelled proteins and nucleic acids in polyacrylamide gels.

Authors:  W M Bonner; R A Laskey
Journal:  Eur J Biochem       Date:  1974-07-01

9.  Size, composition, and structure of the deoxyribonucleic acid of herpes simplex virus subtypes 1 and 2.

Authors:  E D Kieff; S L Bachenheimer; B Roizman
Journal:  J Virol       Date:  1971-08       Impact factor: 5.103

10.  Proteins specified by herpes simplex virus. XII. The virion polypeptides of type 1 strains.

Authors:  J W Heine; R W Honess; E Cassai; B Roizman
Journal:  J Virol       Date:  1974-09       Impact factor: 5.103

View more
  116 in total

1.  Glycoprotein B of herpes simplex virus 2 has more than one intracellular conformation and is altered by low pH.

Authors:  Martin I Muggeridge
Journal:  J Virol       Date:  2012-04-18       Impact factor: 5.103

2.  αvβ3 Integrin Boosts the Innate Immune Response Elicited in Epithelial Cells through Plasma Membrane and Endosomal Toll-Like Receptors.

Authors:  Costanza Casiraghi; Tatiana Gianni; Gabriella Campadelli-Fiume
Journal:  J Virol       Date:  2016-03-28       Impact factor: 5.103

3.  Limiting dilution analysis of specific in vitro anti-herpes simplex virus antibody production by human lymphocytes.

Authors:  M Yasukawa; Y Kobayashi
Journal:  Clin Exp Immunol       Date:  1987-04       Impact factor: 4.330

4.  Regulation of glycoprotein D synthesis: does alpha 4, the major regulatory protein of herpes simplex virus 1, regulate late genes both positively and negatively?

Authors:  M Arsenakis; G Campadelli-Fiume; B Roizman
Journal:  J Virol       Date:  1988-01       Impact factor: 5.103

5.  Potential nectin-1 binding site on herpes simplex virus glycoprotein d.

Authors:  Sarah A Connolly; Daniel J Landsburg; Andrea Carfi; J Charles Whitbeck; Yi Zuo; Don C Wiley; Gary H Cohen; Roselyn J Eisenberg
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

6.  Identification of a site on herpes simplex virus type 1 glycoprotein D that is essential for infectivity.

Authors:  M I Muggeridge; W C Wilcox; G H Cohen; R J Eisenberg
Journal:  J Virol       Date:  1990-08       Impact factor: 5.103

7.  The UL20 gene of herpes simplex virus 1 encodes a function necessary for viral egress.

Authors:  J D Baines; P L Ward; G Campadelli-Fiume; B Roizman
Journal:  J Virol       Date:  1991-12       Impact factor: 5.103

8.  Mapping of a herpes simplex virus type 2-encoded function that affects the susceptibility of herpes simplex virus-infected target cells to lysis by herpes simplex virus-specific cytotoxic T lymphocytes.

Authors:  V C Carter; S R Jennings; P L Rice; S S Tevethia
Journal:  J Virol       Date:  1984-03       Impact factor: 5.103

9.  Effect of acyclovir treatment of primary genital herpes on the antibody response to herpes simplex virus.

Authors:  R L Ashley; L Corey
Journal:  J Clin Invest       Date:  1984-03       Impact factor: 14.808

10.  Immunogenicity of herpes simplex virus glycoproteins gC and gB and their role in protective immunity.

Authors:  J Glorioso; C H Schröder; G Kumel; M Szczesiul; M Levine
Journal:  J Virol       Date:  1984-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.